key: cord-0685515-bvsjzr33
authors: Staadegaard, Lisa; Taylor, Robert J.; Spreeuwenberg, Peter; Caini, Saverio; Simonsen, Lone; Paget, John
title: Monitoring the mortality impact of COVID-19 in Europe: What can be learned from 2009 influenza H1N1p mortality studies?
date: 2020-10-16
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.10.037
sha: a21e83061667ec334e60336a1e91e6c46f25f354
doc_id: 685515
cord_uid: bvsjzr33

Objectives Understanding the proportion of pandemic deaths captured as “laboratory-confirmed” deaths is crucial. We assessed the ability of laboratory-confirmed deaths to capture mortality in the EU during the 2009 pandemic, and examined the likelihood that these findings are applicable to the SARS-CoV-2 pandemic. Methods We present unpublished results from the Global Pandemic Mortality (GLaMOR) project, in which country-specific mortality estimates were made for the 2009 influenza H1N1p pandemic. These estimates were compared to laboratory-confirmed deaths during the 2009 pandemic to estimate the ability of surveillance systems to capture pandemic mortality. Results For the 2009 influenza H1N1p pandemic, we estimated that the proportion of true pandemic deaths captured by laboratory-confirmed deaths was approximately 67%. Several differences (e.g. age groups affected) between the two pandemics make it unlikely that this capture rate will be equally high for SARS-CoV-2. Conclusion The surveillance of laboratory-confirmed deaths in the EU during the 2009 pandemic was more accurate than previously assumed. We hypothesize that this method is less reliable for SARS-CoV-2. Near-real-time excess all-cause mortality estimates, routinely compiled by EuroMOMO, probably form a better indicator of pandemic mortality. We urge more countries to join this project and that national level absolute mortality numbers are presented.

Objectives: Understanding the proportion of pandemic deaths captured as "laboratoryconfirmed" deaths is crucial. We assessed the ability of laboratory-confirmed deaths to capture mortality in the EU during the 2009 pandemic, and examined the likelihood that these findings are applicable to the SARS-CoV-2 pandemic.

We present unpublished results from the Global Pandemic Mortality (GLaMOR) project, in which country-specific mortality estimates were made for the 2009 influenza H1N1p pandemic. These estimates were compared to laboratory-confirmed deaths during the 2009 pandemic to estimate the ability of surveillance systems to capture pandemic mortality.

Results: For the 2009 influenza H1N1p pandemic, we estimated that the proportion of true pandemic deaths captured by laboratory-confirmed deaths was approximately 67%. Several differences (e.g. age groups affected) between the two pandemics make it unlikely that this capture rate will be equally high for SARS-CoV-2.

The surveillance of laboratory-confirmed deaths in the EU during the 2009 pandemic was more accurate than previously assumed. We hypothesize that this method is less reliable for SARS-CoV-2. Near-real-time excess all-cause mortality estimates, routinely compiled by EuroMOMO, probably form a better indicator of pandemic mortality. We urge more countries to join this project and that national level absolute mortality numbers are presented. (WHO, 2009; Briand, Mounts and Chamberland, 2011) . Countries were asked to report laboratoryconfirmed pandemic cases and deaths to the WHO (Briand, Mounts and Chamberland, 2011) . Such data are not typically used to monitor seasonal influenza activity. Instead, most European countries monitor influenza cases rely on syndromic community-and/or hospitalbased surveillance systems and laboratory data (Paget et al., 2007) . Retrospective data analyses periodically assess the mortality impact of seasonal influenza at a country, regional and global level (Iuliano et al., 2018; Paget et al., 2019) .

During the H1N1p pandemic, ECDC published a daily update of laboratory-confirmed H1N1p cases and deaths (ECDC, 2009) . Later two publications (Dawood et al., 2012; Simonsen et al., 2013) using different methods to estimate the regional and global mortality burden of H1N1p.

Both papers concluded that only about 10% of the true global excess mortality burden had been captured by directly counting laboratory-confirmed pandemic deaths. One of these studies, the WHO-funded Global Influenza Mortality Burden project (GLaMOR) project applied a multivariate linear regression model to estimate pandemic respiratory excess mortality in 21 global countries (including 8 from the EU), used these to impute the respiratory mortality burden for all world countries to generate regional and global mortality burden estimates [8].

Here we compare the GLaMOR country-level estimates for the EU (including the United Kingdom), to the laboratory-confirmed H1N1p deaths reported to ECDC through January 2010. We discuss these findings in the context of the debate about laboratory-confirmed Covid-19 deaths and the current pandemic's true mortality burden.

The final 2009 WHO H1N1p pandemic update, published on the 6 th of August 2010, stated that 18,449 laboratory-confirmed pandemic A(H1N1) deaths had been reported globally (WHO, 2010) . In contrast, the GLaMOR project put the number of influenza-associated respiratory excess deaths about an order of magnitude higher, at 123,000-203,000 globally (Simonsen et al., 2013) . This was in broad agreement with the second excess mortality modeling study by CDC, estimating 201, 200 (105, 600 ) associated respiratory deaths, with an additional 83,300 (46,000-179,900) associated cardiovascular deaths (Dawood et al., 2012) . These estimates show that laboratory-confirmed mortality surveillance only captured approximately 10% of all global H1N1p-associated mortality and thus greatly underestimated the actual burden.

Though not previously published, the GLaMOR project generated single-country estimates.

These add up to an estimated 3,369 (range 2,695-4,031) influenza-associated deaths in the EU (including UK) (Simonsen et al., 2013) . As of 18 January 2010, ECDC had recorded a total of 2,269 laboratory-confirmed H1N1p deaths in the EU, of which half were from four countries: UK (16%), France (13%), Spain (12%) and Italy (9%) (ECDC, 2010; Simonsen et al., 2013) . For the entire EU region, national laboratory-based mortality surveillance captured 67% of these pandemic deaths, with wide variation between countries, ranging from -80% to a +47% agreement (Table 1) .

Our analysis shows that laboratory-confirmed H1N1p deaths in Europe were not wildly different from excess mortality estimates, despite variability between EU countries (Simonsen et al., 2013) . In the case of the ongoing SARS-CoV-2 pandemic, however, there are reasons to believe that laboratory-confirmed death surveillance may be a less accurate estimate of COVID-19 mortality. First, the sheer scale of the current pandemic is far larger: as of 4 May 2020, 136,347 COVID-19 deaths have been reported to the ECDC compared to 2,269 deaths overall during the H1N1p pandemic (ECDC, 2010 (ECDC, , 2020 . The age groups with highest mortality are also different, which might cause serious case ascertainment issues.

For example, a recent study estimated that in five EU countries (Belgium, France, Ireland, Norway and Spain), approximately 42-57% of COVID-19 deaths have occurred in 'care homes', where testing appears to occur less systematically (Comas-Herrera et al., 2020); interestingly, in Belgium all deaths previously experiencing clinical COVID-19 symptoms in nursing homes have been attributed to COVID-19 without laboratory confirmation (Sciensano, 2020) . Meanwhile, shortages have prevented widespread testing of suspected deaths as urged by the WHO (WHO, 2020b). These factors together likely are causing a far lower capture rate for COVID-19 deaths in the confirmed tally and inconsistent measurement across the EU region (Leon et al., 2020) . Though the progressive increase in testing capacity for contact tracing purposes could introduce important time-dependent biases in mortality surveillance, it may have also raised the proportion of deaths captured, which could lead to more reliable figures over time.

Optimal public health policies to respond to the pandemic are of the highest importance, and accurate COVID-19 burden estimates (including deaths) are essential for taking the best possible decisions. Currently, most populations are still susceptible, and with no vaccine the economic disruption of the measures currently available to contain the spread of the infection (i.e., more or less restrictive social distancing) a huge socio-economic cost.

If the laboratory-confirmed count is inadequate, other timely data on SARS-CoV-2 mortality are needed. This is where studies of excess all-cause mortality can help. Several studies in Italy and Spain have shown large numbers of excess deaths in certain cities and regions (Economist, 2020) . While the number of laboratory-confirmed deaths is dependent on testing capacity and policy choices, all-cause mortality is free of such bias as it is consistently registered from all deaths. The excess mortality approach has its own limitations and can overestimate the mortality burden attributed to the virus (Li et al., 2018) . However, excess allcause mortality done in a timely fashion potentially provides the most objective estimate of the mortality burden of a pandemic. If all-cause mortality suddenly far exceeds the historical baseline when the pandemic arrives as it has in the COVID-19 period, one can be reasonably sure the pandemic is to blame.

Fortunately, the EuroMOMO network based at the Statens Serum Institute in Copenhagen collects highly timely weekly age-specific mortality data from 24 European countries. Created in 2009 both to monitor seasonal influenza mortality and for pandemic preparedness and response (Mazick et al., 2010) , EuroMOMO publishes aggregate numbers of deaths for the entire region, adjusted for incomplete data. These timely estimates, creating a common mathematical algorithm, are standardized and presented with Z-scores. This is a major asset, allowing for comparison of weekly differences across countries(EURO MOMO, no date). The EuroMOMO surveillance system is a valuable resource for understanding pandemic mortality. For example, the data show clearly that no excess mortality is observable in children and young adults. Because EuroMOMO uses a common mathematical algorithm to compute the COVID-19 burden for Europe, measures of excess mortality and impact are standardized and can be compared across countries. That standardization allows calculation and plotting of z-score graphs to easily see which countries have experienced high COVID-19 mortality and which have not.

It is of great public health interest to see how these differences between countries evolve over the next weeks and months, and on this basis we encourage all WHO Euro countries to contribute mortality data to EuroMOMO. Furthermore, we urge participating countries to explore the possibility of allowing EuroMOMO to present absolute mortality numbers and population rates (per 100,000) for individual countries, which would be of considerable added value (Leon, D. A. et al. 2020) . Doing so could provide public health and government policy makers useful insights as they seek to manage the COVID-19 pandemic's terrible human and economic burden.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 

Challenges of global surveillance during an influenza pandemic

Mortality associated with COVID-19 outbreaks in care homes: early international evidence

Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: A modelling study

Timeline on the pandemic (H1N1) 2009. Available at

influenza A (H1N1) pandemic -daily update

COVID-19 situation update for the EU/EEA and the UK, as of 5

Fatal flaws -Covid-19's death toll appears higher than official figures suggest

Available at

Estimates of global seasonal influenza-associated respiratory mortality: a modelling study

COVID-19: a need for real-time monitoring of weekly excess deaths

Heterogeneity in Estimates of the Impact of Influenza on Population Mortality: A Systematic Review

Higher all-cause mortality in children during autumn 2009 compared with the three previous years: Pooled results from eight European countries

Influenza activity in Europe during eight seasons (1999-2007): an evaluation of the indicators used to measure activity and an assessment of the timing, length and course of peak activity (spread) across Europe

Global Mortality associated with seasonal influenza epidemics: new burden estimates and predictors from the GLaMOR project

COVID-19-EPIDEMIOLOGISCH BULLETIN VAN 5 MEI 2020

Global Mortality Estimates for the 2009 Influenza Pandemic from the GLaMOR Project: A Modeling Study

WHO | World now at the start of 2009 influenza pandemic. World Health Organization

WHO | Pandemic (H1N1) 2009 -update 112. World Health Organization

WHO (2020a) WHO Director-General's opening remarks at the media briefing on COVID-19 -11

WHO (2020b) WHO Director-General's opening remarks at the media briefing on COVID-19 -16